|
    LLY U.S.: NYSE

    Eli Lilly & Co.

    LLYUS
    After Hours
    Last Updated: Sep 17, 2021 7:58 p.m. EDT Delayed quote

    $ 229.95

    -0.15 -0.07%
    After Hours Volume: 582.14K
    Close Chg Chg %
    $230.10 -0.94 -0.41%
    Advanced Charting
    Volume: 4.48M 65 Day Avg: 2.76M
    162% vs Avg
    228.23 Day Range 230.83
    129.21 52 Week Range 275.87

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    LLY Overview

    Performance

    5 Day
    • -3.92%
    1 Month
    • -15.06%
    3 Month
    • 5.28%
    YTD
    • 36.28%
    1 Year
    • 49.25%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 17 Full Ratings

    Recent News

    Read full story

    Eli Lilly & Co. stock underperforms Friday when compared to competitors

    Read full story

    FDA’s Call on Lilly’s Covid Drug Is Lifting a Partner’s Beaten-Down Stock

    Read full story

    Alaska joins Idaho in rationing health care as hospitals are packed with COVID patients, and WHO says Africa is being left behind in vaccine push

    Read full story

    Eli Lilly & Co. stock underperforms Thursday when compared to competitors

    Eli Lilly Gets Expanded FDA EUA for Covid-19 Treatment for Some High-Risk Individuals

    Read full story

    Eli Lilly & Co. stock rises Wednesday, still underperforms market

    Immunovant Taps Renee Barnett as CFO

    U.S. Government Buys More Covid-19 Treatment From Lilly

    Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million

    Eli Lilly to sell 388,000 doses of etesevimab to U.S. gov’t for emergency use in treating COVID-19

    Read full story

    Eli Lilly & Co. stock falls Tuesday, underperforms market

    Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end

    Read full story

    Eli Lilly & Co. stock falls Monday, underperforms market

    Read full story

    Eli Lilly & Co. stock falls Friday, still outperforms market

    Read full story

    Eli Lilly & Co. stock falls Thursday, underperforms market

    Eli Lilly Prices First Sustainability Bond

    ProQR Therapeutics Shares Rise 29% After Research Deal With Lilly

    Read full story

    White House to Announce Drug-Pricing Plan. Pharma Stocks Are Down.

    Lilly, Boehringer Ingelheim Get FDA Breakthrough Designation for Jardiance

    Read full story

    Eli Lilly & Co. stock outperforms market on strong trading day

    Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

    on Zacks.com

    AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

    on Zacks.com

    Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

    on Zacks.com

    Alzheimer's Drug for Roche Partner AC Immune Shows Promise

    on GuruFocus.com

    Regeneron, Lilly Get New COVID Drug Deals From Government

    on Zacks.com

    Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY

    on Zacks.com

    Smart Investors Are Watching This Trend Right Now

    on Motley Fool

    Why AbCellera Biologics Stock Jumped 7% on Wednesday

    on Motley Fool

    Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW

    on Zacks.com

    Top Research Reports for Eli Lilly, Exxon Mobil & Lowe's

    on Zacks.com

    Why Eli Lilly's COVID Antibody Therapy Is Making a Comeback

    on Motley Fool

    Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF

    on Zacks.com

    3 Stocks to Watch in September

    on Motley Fool

    Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs

    on Zacks.com

    Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down

    on Zacks.com

    Here's Why ProQR Stock Surged on Thursday

    on Motley Fool

    Why Shares of Johnson & Johnson Are Down 2% Today

    on Motley Fool

    Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

    on Zacks.com

    Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?

    on Motley Fool

    2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)

    on Motley Fool

    Eli Lilly & Co.

    Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

    Competitors

    Name Chg % Market Cap
    Johnson & Johnson -0.28% $433.7B
    Roche Holding AG -0.65% CHF299.21B
    Roche Holding AG Akt -2.85% CHF299.21B
    Pfizer Inc. -1.30% $246.08B
    AbbVie Inc. -0.32% $190.38B
    Novartis AG -0.58% CHF172.24B
    Merck & Co. Inc. -0.40% $181.45B
    AstraZeneca PLC ADR -1.12% $171.71B
    AstraZeneca PLC -0.96% £124.91B
    Moderna Inc. -2.41% $173.59B
    Competitor Data Provided ByCapital Cube Logo